Evaluation of Nurses’ and Patients’ Overall Satisfaction with New and Previous Formulations of Octreotide Long-acting Release (Sandostatin LAR®): A French Observational Study-Reference-Cited by-同舟云学术

Evaluation of Nurses’ and Patients’ Overall Satisfaction with New and Previous Formulations of Octreotide Long-acting Release (Sandostatin LAR®): A French Observational Study

Published:2020-07-18 Issue:9 Volume:37 Page:3901-3915
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Delemer Brigitte^ORCID,Nguyen-Tan-Hon Thierry^ORCID,Coriat Romain^ORCID,Smith Denis^ORCID,Schillo Frank^ORCID,Raingeard Isabelle,Sobhani Iradj^ORCID,Etienne Pierre-Luc^ORCID,Decoudier Benedicte^ORCID,Bisot-Locard Ségolène^ORCID,Santos Alexandre^ORCID,Raverot Gerald^ORCID,Cadiot Guillaume^ORCID

Funder

Novartis Pharma

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12325-020-01429-4.pdf

Reference22 articles.

1. (HAS), H. A. de S. (2019) Avis Sandostatine LAR. https://www.has-sante.fr/upload/docs/evamed/CT-15938_SANDOSTATINE_LP_QD_INS_Avis1_CT15938.pdf.

2. Adelman D, et al. Evaluation of nurse preferences between the lanreotide autogel new syringe and the octreotide long-acting release syringe: an international simulated-use study (PRESTO). Adv Therapy. 2020. https://doi.org/10.1007/s12325-020-01255-8.

3. Anthony L, Freda PU. From somatostatin to octreotide LAR: Evolution of a somatostatin analogue. Curr Med Res Opin. 2009. https://doi.org/10.1185/03007990903328959.

4. Carlson J, et al. Rituximab for subcutaneous delivery: clinical management principles from a nursing perspective. Int J Nurs Pract. 2015. https://doi.org/10.1111/ijn.12413.

5. Chanson P, et al. Acromegaly. Best Pract Res Clin Endocrinol Metab. 2009. https://doi.org/10.1016/j.beem.2009.05.010.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Key Device Attributes for Injectable Somatostatin Receptor Ligand Therapy in Acromegaly and Neuroendocrine Tumours;Advances in Therapy;2023-08-12

2. PRESTO 2: An International Survey to Evaluate Patients’ Injection Experiences with the Latest Devices/Formulations of Long-Acting Somatostatin Analog Therapies for Neuroendocrine Tumors or Acromegaly;Advances in Therapy;2022-12-11